Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Officials in New Delhi are worried that the US could target other goods, especially pharmaceuticals, which in 2016 comprised 16 per cent of Indian exports to the country....
...The approval gives UK biotech company GW Pharmaceuticals a head start in a market potentially worth billions of dollars....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...You Don’t Own Me: How Mattel v....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...“We’ve developed the world’s first meter-dose system for cannabis,” says Perry Davidson, Syqe’s chief executive....
...Harley-Davidson, the US motorcycle company, surged 19.8 per cent to $54.25 on an unconfirmed takeover rumour reported by The Fly, a financial website....
...New York-listed shares of Israeli drugmaker Teva Pharmaceuticals rose more than 1 per cent to $64.16, after the company offered to buy US drugmaker Mylan....
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...Pharmaceutical companies were buoyed on Tuesday by news that activist investor Bill Ackman had teamed up with generic drugmaker Valeant Pharmaceuticals in pursuit of Allergan, a sign that deal activity in...
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Just one of hundreds of raids carried out worldwide through Interpol’s Operation Pangea V, nearly 200 police and regulatory agencies combined efforts to clamp down on the complex multimillion dollar international...
...Mr Davidson says areas of employment demand in Sydney include pharmaceutical and medical devices, and fast-moving consumer goods, along with specialist roles within the financial sector, such as wealth management...
...Motorcycle manufacturer Harley-Davidson fell 7.8 per cent to $34.31. Quarterly results appeared strong with retail sales up 5.4 per cent year-on-year, much better than expected....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
International Edition